Nurix Therapeutics Inc(NRIX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:21 PM ET (Korea 10/31 05:21)
Full metrics table
| Index | RUT | P/E | 11.59 | EPS (ttm) | 2.31 | Insider Own | 4.76% | Shs Outstand | 109.2M | Perf Week | 5.76% |
| Market Cap | 2.93B | Forward P/E | - | EPS next Y | -190.38% | Insider Trans | -3.12% | Shs Float | 104.0M | Perf Month | 14.82% |
| Enterprise Value | 1.94B | PEG | - | EPS next Q | -0.41 | Inst Own | 105.55% | Short Float | 19.81% | Perf Quarter | 15.42% |
| Income | 0.29B | P/S | 4.17 | EPS this Y | 177.12% | Inst Trans | -6.82% | Short Ratio | 12.18 | Perf Half Y | 59.43% |
| Sales | 0.70B | P/B | 3.02 | EPS next 5Y | 32.31% | ROA | 34.33% | Short Interest | 20.61M | Perf YTD | 41.28% |
| Book/sh | 8.87 | P/C | 2.79 | EPS past 3/5Y | 6.31% -2.04% | ROE | 43.99% | 52W High | -5.07% ($28.23) | Perf Year | 109.7% |
| Cash/sh | 9.6 | P/FCF | 7.92 | Sales past 3/5Y | 29.55% 36.35% | ROIC | 28.62% | 52W Low | 133.04% ($11.50) | Perf 3Y | 409.51% |
| Dividend Est. | - | EV/EBITDA | 6.37 | EPS Y/Y TTM | 184.54% | Gross Margin | 97.74% | Volatility(W/M) | 5.3% 5.19% | Perf 5Y | -19.88% |
| Dividend TTM | - | EV/Sales | 2.77 | Sales Y/Y TTM | 738.76% | Oper. Margin | 41.27% | ATR (14) | 1.2 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.44 | EPS Q/Q | 560.95% | Profit Margin | 42.01% | RSI (14) | 63.81 | Recom | 1.21 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.44 | Sales Q/Q | 8426.27% | SMA20 | 9.07% ($24.57) | Beta | 1.82 | Target Price | $34.5 |
| Payout | - | Debt/Eq | 0.07 | Earnings | 2026/10/12 | SMA50 | 7.28% ($24.98) | Rel Volume | 1.37 | Prev Close | $27.12 |
| Employees | 317 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | 887.15% 2664.3% | SMA200 | 32.83% ($20.18) | Avg Volume(3M) | 1.69M | Price | $26.8 |
| IPO | 2020/7/24 | Option/Short | Yes/Yes | Trades | 18429 | Volume | 2,311,460 | Change | -1.18% |
A clinical-stage biotech developing targeted protein degradation–based therapeutics. The company uses a technology platform that selectively degrades disease-causing proteins to develop treatments such as anticancer therapies, operating a model that combines its own pipeline with major pharmaceutical partnerships. It has established itself as a differentiated anticancer biotech through its targeted protein degradation approach.
Over the past 1 year, on the higher side
5% below its 1-year high.
Traded more than usual. That is 137% of its average volume.
NRIX makes money exceptionally well
Of every $100 in sales, $41.27 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +177.1% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company earning $100 a year, you would pay $1,159. Peers typically go for $1,345.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -19.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 105.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #75 of 597 in the industry
Based on market cap of $3B.
IDYA#73 Ideaya Biosciences Inc $3B PER - 
DNLI#74 Denali Therapeutics Inc $3B PER - NRIX#75 Nurix Therapeutics Inc $3B PER 11.6 
BEAM#76 Beam Therapeutics Inc $3B PER - 
VRDN#77 Viridian Therapeutics Inc $3B PER - 
FAQ
What kind of company is NRIX?
NRIX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NRIX?
The market cap of NRIX is approximately $2.9B, ranking 1,783 within its sector.
What is the P/E ratio of NRIX?
NRIX has a P/E ratio of approximately 11.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for NRIX?
NRIX has recorded a 52-week high of $28.23 and a low of $11.50.
